Trial Testing Low-dose Psychedelics in PD

This would be an interesting trial to be a part of:

"The trial’s primary goal is to examine the effect of low doses of psilocybin and LSD on cognitive and emotional dysfunction in patients with Parkinson’s, as well as to understand their mechanism of action.

Specifically, the trial will assess the safety and efficacy of repeated low doses of psilocybin and LSD and their effects on well-being, emotional and cognitive attention, and biological markers of neuroplasticity, which is the ability of neural networks — the large-scale intertwined circuits that connect nerve cells to one another — in the brain to grow and reorganize, such as individual neurons making new connections.

Secondary goals include the effects of low doses of psychedelics on cognition performance measures of memory and executive functioning, which are commonly impaired in Parkinson’s, as well as emotion regulation and biological markers of well-being."

That’s great. However, it’s important to remember that Parkinson’s disease is a complex disorder. There’s no single treatment that works for everyone.